Mangoceuticals, Inc. (MGRX)
| Market Cap | 6.71M -73.0% |
| Revenue (ttm) | 315,227 -38.9% |
| Net Income | -16.57M |
| EPS | -1.12 |
| Shares Out | 17.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 212,901 |
| Open | 0.3895 |
| Previous Close | 0.3901 |
| Day's Range | 0.3730 - 0.3950 |
| 52-Week Range | 0.1620 - 2.7500 |
| Beta | 2.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About MGRX
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men’s wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and acc... [Read more]
Financial Performance
In 2025, Mangoceuticals's revenue was $456,021, a decrease of -25.96% compared to the previous year's $615,873. Losses were -$21.82 million, 129.5% more than in 2024.
Financial StatementsNews
Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-l...
Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-l...
Mangoceuticals Quarterly report: Q2 2026
Mangoceuticals has published its Q2 2026 quarterly earnings report on August 13, 2026.
Mangoceuticals’ partner Nuclea signs MOU with New Mining on reactor
Mangoceuticals (MGRX) announced that its merger partner, Nuclea Energy, has signed a non-binding memorandum of understanding with New Mining, a Miami-headquartered provider of high-density digital inf...
Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
The MOU will assess the technical feasibility of integrating Nuclea's modular reactor technology into New Mining's data center operations, with a phased evaluation path toward a cumulative 100 MWe of ...
Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
MOU will assess the technical feasibility of integrating Nuclea's modular reactor technology into New Mining's data center operations, with a phased evaluation path toward a cumulative 100 MWe of behi...
Mangoceuticals' Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
The MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab and engagement with the U.S. Department of Energy and Nuclear Regulatory Commission to advance the Morpheu...
Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development
The MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab to advance the Morpheus microreactor toward demonstration and deployment Salt Lake City, Utah--(Newsfile C...
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
Dallas, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced it has received an additional 180-calendar-day extension from t...
Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor
Transaction positions Nuclea to fund the development and commercialization of its lead-cooled, factory-built microreactor as AI and data center growth drives a generational expansion in U.S. electrici...
Mangoceuticals enters business combination agreement with Nuclea Energy
Mangoceuticals (MGRX) announced that it has entered into a definitive business combination agreement with Nuclea Energy, an advanced nuclear technology company founded in August 2023 and headquartered...
Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
Business Combination Agreement to Bring Nuclea's Lead-Cooled Morpheus Microreactor to the Public Markets Amid Surging Power Demand from AI and Data Centers DALLAS, TEXAS, July 30, 2026 (GLOBE NEWSWIRE...
Mangoceuticals Quarterly report: Q1 2026
Mangoceuticals has published its Q1 2026 quarterly earnings report on May 19, 2026.
Mangoceuticals Annual report: Q4 2025
Mangoceuticals has published its Q4 2025 annual report on April 1, 2026.
Why Is Mangoceuticals, Inc. Stock (MGRX) Up Today?
Mangoceuticals, Inc. ($MGRX) stock rocketed higher on Monday alongside a filing with the Securities and Exchange Commission (SEC) from the men’s wellness products and services company. This filing upd...
Mangoceuticals files civil lawsuit against Clarity Ventures
Mangoceuticals (MGRX) announced that it has filed a civil lawsuit against Clarity Ventures, its former technology consulting and software development firm. The lawsuit, filed in Texas state court, see...
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals,” the “Company,” or “MangoRx”), a company focused on developing, marketing, and selling health an...
Mangoceuticals announces patent filing for MGX-0024
Mangoceuticals (MGRX) “announced the filing of a Patent Cooperation Treaty (PCT) international application on February 26, 2026, to secure broad global patent protection for the antiviral animal feed ...
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telem...
Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure teleme...
Here’s Why Mangoceuticals Stock (MGRX) Rocketed Today
Mangoceuticals stock saw strong momentum today alongside positive results from its TRT program.
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company” or “MangoRx”), a c...
Mangoceuticals Registration statement: Registration Filing
Mangoceuticals filed a registration statement on January 23, 2026, providing details about a securities offering with the SEC.
Mangoceuticals files to sell 2.64M shares of common stock for holders
17:33 EST Mangoceuticals (MGRX) files to sell 2.64M shares of common stock for holders
Mangoceuticals Registration statement: Registration Filing
Mangoceuticals filed a registration statement on January 13, 2026, providing details about a securities offering with the SEC.